Introduction
In stimulated normal phagocytes, NADPH oxidase catalyzes the reduction of oxygen to superoxide. Superoxide and its more potent microbicidal derivatives (e.g., hydrogen peroxide, hypohalous acids) are important for killing invading microorganisms. In chronic granulomatous disease (CGD), an uncommon inherited disorder of the innate immune system, the primary defect occurs in any one of four genes encoding phox proteins of the phagocyte NADPH oxidase complex. Gp91-phox and p22-phox together form flavocytochrome b 558 , the catalytic core of the enzyme, while p47-phox and p67-phox are found in the soluble fraction of resting phagocytes. The association of p47-phox and p67-phox with the flavocytochrome at the plasma or phagosomal membrane is crucial for enzyme activation. In CGD patients, phagocyte NADPH oxidase activity is absent or occurs at very low levels. Consequently, patients are highly susceptible to severe, The p47-phox-deficient form of CGD (A47 o CGD), which accounts for about 20% of all CGD cases, is inherited in an autosomal recessive manner and caused by mutations in the gene NCF-1. A47 o CGD is unique among the four forms of the disease, in that a common mutation has been identified in ~ 95% of affected alleles analyzed worldwide. Ninety-five out of 104 unrelated patients reported to date were homozygous and a further seven were heterozygous for a dinucleotide deletion ( GT) in a GTGT sequence at the beginning of exon 2 of NCF-1 [3] [4] [5] [6] [7] [8] [9] . The deletion predicts a frameshift and a premature stop codon at residue 51 and leads to complete absence of p47-phox protein from the patients' phagocytes (A47 o CGD) 3 . Only eight other mutations have been identified in NCF-1 4, 8, 10, 11 . In contrast, the mutations that cause the other
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A47
o CGD is also unusual in that it is at least four times more common than the other autosomal recessive forms of the disease. Defects in the genes for p22-phox (CYBA) and p67-phox (NCF-2) each account for approximately 5% or less of all cases. The remaining 70% of cases are inherited in an X-chromosome-linked manner and are caused by mutations in the gp91-phox gene, CYBB 1, 13 .
NCF-1 has at least two pseudogenes, each of which are highly homologous (~98% identical) to the functional gene and colocalize with it to chromosome 7q11.23 7, [14] [15] [16] [17] [18] . It is now apparent that the relatively high incidence of A47 o CGD and the predominance of the GT mutation are due to recombination events between NCF-1 and its pseudogenes resulting from their close proximity, their high degree of similarity and the presence within each gene of multiple recombination hotspots 7, 9, 15, 19 .
Interestingly, these genes occur in a region of chromosome 7 that contains large (~200-400 kb) duplicated segments (duplicons) of DNA, in each of which lies a single copy of NCF-1 or NCF-1, in addition to other gene/pseudogene sequences. The complex 7q11.23 region, which has been difficult to map due to the high level of duplication, has been intensively studied as it also contains the locus of Williams-Beuren syndrome [16] [17] [18] 20 . 
Methods
Collection of blood samples and preparation of DNA Protocols and consent forms for the collection of blood samples were approved by the Human Subjects Committee of the Scripps Office for the Protection of Research Subjects. Whole blood was collected with EDTA as an anticoagulant, and genomic DNA was isolated using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). Custom synthesized oligonucleotide primers were purchased from Sigma-Genosys.
Determination of the ratio of GT-to GTGT-containing sequence
Two independent methods were used to estimate the ratio of GT-to GTGT-containing sequence in genomic DNA samples. In the first method, exon 2 of NCF-1/ NCF-1 was amplified using intronic primers 2LB2 (GTGCACACAGCAAAGCCTCT) and 2RB2 (CTAAGGTCCTTCCCAAAGGGT). Reaction conditions have been described previously 8 .
PCR-amplified fragments were purified using a QIAquick PCR purification kit (Qiagen, Valencia, CA) and sequenced using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA) and an ABI Prism 310 Genetic
Analyzer. Nucleotide peak heights were measured directly using the instrument software over a 27 bp stretch of sequence, corresponding to nucleotides 81-107 of the p47-phox cDNA. At each position, the ratio of nucleotide peak heights was calculated and a mean ratio determined for the entire section. Peak heights were not measured at the three positions within this stretch at which nucleotides in the pseudogene and functional gene coincided ( Figure 2 ). When peak heights were measured over the entire exon, the calculated ratios were very similar to those obtained by measurements over the 27 bp stretch. In the second method, radiolabeled PCR products encompassing the start of exon 2 were separated on denaturing acrylamide gels and quantified. DNA from 62 bp 5' from the start of exon 2 through 38 bp into exon 2 was amplified using 32 P end-labeled 2LB2 and unlabeled cDNA2R (TCCGACAGGTCCTGCCA). Primer 2LB2 was end-labeled using 90 ng 2LB2, 180
µCi -32 P ATP, 0.5 µl T4 10x buffer, 2.5 U T4 polynucleotide kinase in a final volume of 5 µl.
The radiolabeling mixture was incubated at 37°C for 30 minutes, after which the kinase was inactivated by heating to 65°C for 20 minutes. 
Allele-specific PCR
In order to avoid coamplification of DNA with the GT deletion, we used an allele-specific PCR strategy to amplify the entire functional NCF-1 and, where present, the GTGT-containing NCF-1. The amplification reactions, which are described fully in 8 , used either forward or 8 reverse primers including the GTGT at the beginning of exon 2. Allele-specificity of the reactions was checked by sequencing the reaction products to ensure that only GTGT-containing sequence was present 7, 8 . Purification and sequencing of amplified fragments was performed as described above. Sequence numbering in this report is based on the convention that +1 is the A of the ATG initiator codon. This is 12 nucleotides less than the numbering of the cDNA sequence for NCF-1 in GenBank (accession numbers M25665 and M26193).
Allele-specific RT-PCR
Total RNA was isolated from whole blood using the RNeasy Blood Mini Kit (Qiagen). Reverse transcription (RT)-PCR was performed exactly as described previously using the SuperScript
Preamplification System for first-strand cDNA synthesis 8 . Briefly, two allele-specific PCRs were performed. In the first, a fragment from the beginning of exon 1 to the beginning of exon 2 was amplified with primers cDNA1F and GTGT-R. In the second, primers cDNAGTGT and cDNA11R were used to amplify from the start of exon 2 to the end of exon 11. Primer sequences are given in Table 1 of the previous publication 8 . The allele specificity of the RT-PCR products was checked by sequencing into the region of the allele-specific primer to ensure that only GTGT sequence was present.
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Results and Discussion
We have shown previously that examination of the electropherogram peak heights for the p47-phox pseudogene and functional gene sequence in exon 2 can be a useful, preliminary guide for distinguishing between patients with the common GT/ GT genotype and those with rare non-GT mutations 8 . In the relatively small number of control individuals (unaffected by CGD) included in that previous study, the ratio of GT-containing sequence to GTGT-containing sequence was approximately 2:1, consistent with the presence of two copies of NCF-1 and a single copy of the functional gene [15] [16] [17] . In obligate heterozygous carriers ( GT/GTGT) of the predominant form ( GT/ GT) of A47 o CGD, the peak height ratios were predictably much higher
.
Three different GT:GTGT ratios in the general population
Our earlier findings therefore raised the possibility that a simple measurement of the ratio of GT to GTGT sequence could be used to reliably identify carriers of the GT mutation. Indeed, a method utilizing this general principle has recently been published 21 .
To study further the relationship between the NCF-1 and NCF-1 genes and to assess the reliability of this technique, we analyzed DNA from a group of 53 unaffected and unrelated control individuals and additional obligate carriers of the disease. Using oligonucleotide primers that do not distinguish between the gene and its pseudogenes, we amplified and sequenced fragments spanning exon 2. We initially compared electropherogram peak heights over a 27 bp stretch of double sequence, as this method had yielded results in our previous study consistent with published data. As shown in Figures 2 and   3 , analysis of genomic DNA from this large group of control individuals revealed that three distinct
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In 44 out of the 53 control individuals (Figure 3) , the ratio of GT sequence to GTGT sequence was approximately 2:1 (2.25 ± 0.14; mean ± SD), as we had previously observed and consistent with data from human genome sequencing. In seven persons, the amount of GTGT sequence was approximately equal to that of the GT sequence, giving a ratio of 1:1 (1.02 ± 0.05). Surprisingly, in DNA from two control subjects the ratio of GT to GTGT sequence was completely reversed at approximately 1:2 (0.46 ± 0.03). As previously observed, 8, 21 most obligate carriers of the GT mutation had a much higher ratio of GT to GTGT sequence (top panel of Figure 2 ).
Measuring electropherogram peak height ratios is not necessarily a reliable way to estimate relative numbers of each gene as it depends not only on the NCF-1 and NCF-1 DNA amplification reactions proceeding with equal efficiency but also on the sequencing reaction yielding quantitative data. To verify our results, we utilized a second independent method, using Table 1 show that the results from the two methods were generally in good agreement. The largest difference occurred with the group of seven A47 o CGD carriers, where the frequency of the functional gene appeared to be consistently underestimated based on peak height measurements and overestimated using the gel-based technique, assuming a theoretical value of five (see below).
However, the mean value with the two methods (4.83) was very close to the theoretical value and in good agreement with the results of Dekker et al 21 , who used a similar technique with a fluorochrome-labeled forward primer.
NCF-1 containing GTGT at the start of exon 2
The GT:GTGT ratios of approximately 2, 1 and 0.5 that we have determined experimentally in unaffected controls are most easily explained by the presence in the general population of a second, previously unidentified type of NCF-1 pseudogene (or duplicate copy of the gene)
containing GTGT at the start of exon 2 rather than the signature GT. We refer to this novel pseudogene as Type II, and the more common, GT-containing pseudogenes as Type I, but for this classification do not take into account possible single nucleotide differences between Evidence to support the existence of the genotypes presented in Figure 5 was provided by analysis of genomic DNA from the parents and siblings of one of the two control individuals identified as having a GT: GTGT ratio of ~0.5 (1:2) in Figure 3 (referred to here as subject P).
For our model to be correct, both his parents would have to have at least one copy of a Type II
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NCF-1 pseudogene within their genome. As shown in the pedigree of this family (Figure 6 ), the mother and father of subject P both had GT:GTGT ratios of 1:1. This is internally consistent with them having copies of each of the two extended haplotypes, allowing subject P (indicated by the asterisk) to have inherited a Type II NCF-1 from each of his parents. Both siblings of subject P had GT:GTGT ratios of 1:1. Additional support for our model came from experiments in which we mixed equal amounts of DNA (measured spectrophotometrically) from three different 2:1 control individuals with DNA from a single A47 o CGD patient homozygous for GT. These samples represent the first and final genotypes in Figure 5 and as would be predicted, when combined gave GT:GTGT ratios very similar to those of most A47 o carriers -close to the theoretical value of 5:1 ( Figure 3 ).
Obligate carriers of GT can have a GT:GTGT ratio of 2:1
As indicated in Figure 5 (Figure 3) . In one case, we could not categorically rule out the possibility that a de novo GT mutation had occurred in a germline cell, raising the possibility that the parent with a 2:1 ratio was unaffected and not a carrier. However, in the second case the evidence was much stronger that the mother, whose GT:GTGT ratio was 2:1, was indeed a carrier. As shown in this family's pedigree (Figure 7) , two daughters had A47 o CGD and were
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She must therefore have acquired the more common (2:1) haplotype from her father (who had a ratio 5:1) and the less common (1:2) haplotype from her mother. Two parents of homozygous GT patients with GT:GTGT ratios of 2:1 were also identified in a previous study 21 but de novo GT mutations were not excluded.
Origin of the GTGT-containing pseudogene
There appear to be two main possibilities for the origin of the GTGT-containing (Type II) pseudogene. One is that it represents a duplication of the functional gene in which the deletion of GT has not (yet) occurred, perhaps because this duplication is more recent from an evolutionary standpoint. A second possibility is that it represents the previously unidentified product of the reciprocal crossover of a DNA fragment between the functional NCF-1 gene and one of its pseudogenes. In an attempt to distinguish between these events, we analyzed additional markers previously shown to discriminate between the gene and its pseudogenes. These included the C/T transition in intron 1, the 20 bp stretch in intron 2 that is duplicated in the pseudogenes, and the single nucleotide differences G269A, A496G, A558G and A849G 9, 15 . We used an allele-specific strategy that amplifies only GTGT-containing DNA (i.e., NCF-1 and the Type II pseudogene) and sequenced the appropriate regions of introns 1 and 2, and exons 2 (to confirm the absence of GT), 4, 6 and 9 in their entirety. As expected, in nine unaffected controls with GT:GTGT ratios of 2:1, only NCF-1 sequence was detected at all these positions. In contrast, in the two control individuals with GT:GTGT ratios of 1:2, both functional gene and pseudogene sequence was observed at each of the markers except the C/T transition in intron 1 (where only C was detected). These
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Although it is not possible to conclusively distinguish between the two mechanisms by which the Type II pseudogene has arisen, based on our analysis of these gene/pseudogene markers we believe that it most likely represents the product of a reciprocal crossover of a DNA fragment between NCF-1 and one copy of NCF-1. Figure 8 illustrates one possible crossover mechanism.
As a result of this crossover event, one pseudogene acquires a GTGT-containing fragment from NCF-1 (shown in green) to generate a Type II pseudogene. Concurrently, the previously functional NCF-1 acquires the GT mutation originating in the corresponding fragment of pseudogene (shown in red), thereby generating the common A47 o CGD allele. In the two 1:2 control subjects studied, only functional gene sequence was observed at the C/T transition in intron 1, suggesting that the 5' cross-over site is upstream of this position. This is consistent with previous reports regarding the most common crossover sites within NCF-1/ NCF-1 7, 9 . Given the reported variation in size of recombination fragments in A47 o patients 7, 9 , it is likely that a similar heterogeneity will be seen in the size of the NCF-1 fragment inserted to form the Type II pseudogene.
Besides the C/T transition, only one additional marker has been described that is 5' of the start of exon 2 and distinguishes between NCF-1 and its pseudogenes. Görlach et al 15 reported that all pseudogene clones analyzed contained a single 30 bp stretch of sequence in intron 1 that was present as a tandem duplication in the functional gene clones. We analyzed this region in genomic DNA to determine if it was a potentially useful marker to identify the upstream site of recombination. Using allele-specific PCR we amplified and sequenced the fragment from exon 1 to the start of exon 2 in ten control individuals (all with GT:GTGT ratios of 2:1) and confirmed in each case that only GTGT-containing sequence was present. DNA from five persons Therefore, it does not reliably distinguish between gene and pseudogene and is not likely to be a good marker to map crossover sites.
One advantage of our model is that it explains the intriguing anomaly that while there is a pool within the population of additional DNA fragments containing GT (in GT/ GT patients and carriers of the mutation) no corresponding fragment had been identified that contains GTGT.
As crossover events between NCF-1 and NCF-1 most commonly account for the insertion of GT in NCF-1 7, 9 and crossovers are reciprocal in nature, it was puzzling that a GTGT-bearing fragment had not been located in the genome. The Type II pseudogene identified here appears to carry this missing fragment. Although the crossover mechanism shown in Figure 8 would generate an equal number of CGD and 1:2 extended haplotypes, negative selection pressure would tend to remove the CGD haplotype from the population. This has apparently resulted in an approximate 50-fold excess within the population of the 1:2 haplotype (with an incidence of 1 in 10) compared to the CGD haplotype (1 in 500).
Type II "pseudogene" may be functional
The 5' regulatory regions of the p47-phox pseudogenes are almost identical to the equivalent region of the functional gene and the pseudogenes are known to be transcriptionally active 15, 19 .
With GT deleted at the start of exon 2, the predicted translation product of the Type I pseudogene is 50 amino acids in length, with only the first 25 being identical to the corresponding region of p47-phox. This altered, truncated polypeptide is unlikely to be functional and to our knowledge, it has never been detected. Of the other well-characterized differences that distinguish between the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From gene and its pseudogenes, two are intronic and unlikely to affect transcription and splicing and those that are exonic are single nucleotide changes that are mostly silent. Only two predict amino acid substitutons, G269A and A496G predicting Arg90His and Asn166Asp, respectively, and these changes may not lead to a loss of function. Based on our relatively small sample, 17% (9 out of 53) of the healthy population has at least one copy of Type II NCF-1. Sequencing of allele-specific RT-PCR products from subject P revealed heterozygosity at the same exonic gene/pseudogene markers as found in GTGT-containing genomic DNA, confirming that Type II NCF-1 is transcribed. With a paucity of mutations within the coding region, it is feasible that it produces functional protein but the analysis required to show this conclusively is beyond the scope of this study.
In conclusion, we have provided evidence for the presence in the general population of a previously undetected NCF-1 pseudogene/gene chimera. In contrast to the predominant A47 o CGD allele, which arises from the insertion of GT into NCF-1 rendering it non-functional, this new fusion allele appears to represent the insertion of a GTGT-bearing fragment into a nonfunctional pseudogene. Whether or not the resulting gene is functional remains to be determined, but in either case it is likely to be innocuous as, to date, we have only found it in combination with functional NCF-1. However, the presence of at least two NCF-1/ NCF-1 extended haplotypes in the population further complicates the detection of GT carriers as approximately one in ten will have GT:GTGT ratios of 2:1 and be indistinguishable from the majority of unaffected individuals.
For a All samples included under Method 2 were also analyzed using Method 1.
b Mean ± S.D.
c Average of the two methods with predicted ratio in parenthesis. Table 1 , together with confirmatory data using a second, independent method. It is flanked by its two pseudogenes 16, 18 , which are either of Type I ( GT) or Type II (GTGT).
n.d., not determined
In the majority of A47 o CGD patients, both copies of NCF-1 contain the GT mutation. Their carrier parents are heterozygous for the mutation and while most have a GT:GTGT sequence ratio of 5:1 as shown, approximately 10% would be predicted to show a ratio of 2:1 (see text). These data indicate that the mother carries the GT mutation in NCF-1 on one copy of chromosome 7 and one each of the type I and type II pseudogenes on the other copy. All other details are the same as Figure 5 . 
